Indoleamine 2,3-dioxygenase (IDO)-activity in Severe Psychiatric Disorders: A Systemic Review

被引:6
|
作者
Fellendorf, Frederike T. [1 ]
Bonkat, Nina [1 ]
Dalkner, Nina [1 ]
Schoenthaler, Elena M. D. [1 ]
Manchia, Mirko [2 ,3 ]
Fuchs, Dietmar [4 ]
Reininghaus, Eva Z. [1 ]
机构
[1] Med Univ Graz, Dept Psychiat & Psychotherapeut Med, Graz, Austria
[2] Univ Cagliari, Dept Med Sci & Publ Hlth, Sect Psychiat, Cagliari, Italy
[3] Dalhousie Univ, Dept Pharmacol, Halifax, NS, Canada
[4] Med Univ Innsbruck, Inst Biol Chem, Bioctr, Innsbruck, Austria
关键词
Kynurenine to tryptophan ratio; Indoleamine; 2; 3-dioxygenase; IDO; Psychiatry; Inflammation; Tryptophan catabolism; INCREASED SERUM NEOPTERIN; KYNURENINE PATHWAY; BIPOLAR DISORDER; TRYPTOPHAN-METABOLISM; IMMUNE ACTIVATION; MAJOR DEPRESSION; ASSOCIATION; DEGRADATION; EXPRESSION; SEROTONIN;
D O I
10.2174/1568026622666220718155616
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background Indoleamine 2,3-dioxygenase (IDO) activity is induced by cellular immune activation and therefore associated with inflammatory diseases, among others psychiatric disorders. This review aims to elucidate IDO activity reflected by kynurenine (KYN) to tryptophan (TRP) ratio in severe mental disorders. Methods A systematic literature search in MEDLINE and EMBASE was conducted targeting clinical trials in English language measuring KYN/TRP in individuals with a diagnosis of depression, bipolar disorder, or schizophrenia. Results Five out of 15 studies found higher levels of KYN/TRP in depression compared to a control group while the same amount found no difference. Moreover, three studies showed lower levels. In bipolar disorder, four out of six, and in psychotic disorders, three out of four trials found higher levels in patients compared to controls. There are only two studies comparing KYN/TRP in major depression and bipolar disorder, showing conflicting results. Eight studies focused on associations between KYN/TRP and clinical parameters, whereas two studies found positive correlations between KYN/TRP and severity of depressive symptoms. In contrast, four studies did not show an association. IDO activity during specific psychiatric treatment was analyzed by eight studies. Conclusion In summary, this review demonstrates an inconsistency in the findings of studies investigating KYN/TRP in severe mental disorders. Although there are hints that inflammation associated with TRP catabolism towards the KYN pathway via elevated IDO activity seems likely, no conclusive statements can be drawn. Presumably, the consideration of influencing factors such as inflammatory processes, metabolic activities and psychological/neuropsychiatric symptoms are pivotal for a deeper understanding of the underlying mechanisms.
引用
收藏
页码:2107 / 2118
页数:12
相关论文
共 50 条
  • [1] Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
    Yang, Pengbo
    Zhang, Junhua
    BIOMEDICINES, 2023, 11 (07)
  • [2] Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus
    Romani, Luigina
    Zelante, Teresa
    De Luca, Antonella
    Bozza, Silvia
    Bonifazi, Pierluigi
    Moretti, Silvia
    D'Angelo, Carmen
    Giovannini, Gloria
    Bistoni, Francesco
    Fallarino, Francesca
    Puccetti, Paolo
    MEDICAL MYCOLOGY, 2009, 47 : S154 - S161
  • [3] Increased indoleamine 2,3-dioxygenase (IDO) activity in idiopathic generalized epilepsy
    Liimatainen, Suvi
    Lehtimaki, Kai
    Raitala, Annika
    Peltola, Maria
    Oja, Simo S.
    Peltola, Jukka
    Hurme, Mikko A.
    EPILEPSY RESEARCH, 2011, 94 (03) : 206 - 212
  • [4] Indoleamine 2,3-dioxygenase (IDO) Activity in Placental Compartments of Renal-Transplanted Pregnant Women
    do Prado, Karen Matias
    Correa-Silva, Simone
    Oliveira, Leandro Gustavo
    Saraiva Camara, Niels Olsen
    Ono, Erica
    Sandri, Silvana
    Tourino, Melissa Cavalheiro
    Campa, Ana
    Lima, Larissa de Sa
    Scavone, Cristoforo
    Bevilacqua, Estela
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2014, 72 (01) : 45 - 56
  • [5] The role of indoleamine 2,3-dioxygenase in allergic disorders
    Esmaeili, Seyed-Alireza
    Hajavi, Jafar
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (04) : 3297 - 3306
  • [6] Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
    Fujiwara, Yu
    Kato, Shumei
    Nesline, Mary K.
    Conroy, Jeffrey M.
    DePietro, Paul
    Pabla, Sarabjot
    Kurzrock, Razelle
    CANCER TREATMENT REVIEWS, 2022, 110
  • [7] The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy
    von Bubnoff, D.
    Bieber, T.
    ALLERGY, 2012, 67 (06) : 718 - 725
  • [8] Indoleamine 2,3-dioxygenase (IDO)-1 and IDO-2 activity and severe course of COVID-19
    Guo, Lihui
    Schurink, Bernadette
    Roos, Eva
    Nossent, Esther J.
    Duitman, Jan Willem
    Vlaar, Alexander P. J.
    van der Valk, Paul
    Vaz, Frederic M.
    Yeh, Syun-Ru
    Geeraerts, Zachary
    Dijkhuis, Annemiek
    van Vught, Lonneke
    Bugiani, Marianna
    Lutter, Rene
    JOURNAL OF PATHOLOGY, 2022, 256 (03) : 256 - 261
  • [9] A potential role for indoleamine 2,3-dioxygenase (IDO) in Rhodococcus equi infection
    Heller, M. C.
    Drew, C. P.
    Jackson, K. A.
    Griffey, S.
    Watson, J. L.
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2010, 138 (03) : 174 - 182
  • [10] Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy
    Guo, Yixuan
    Liu, Yu
    Wu, Wei
    Ling, Daishun
    Zhang, Qiao
    Zhao, Peng
    Hu, Xi
    BIOMATERIALS, 2021, 276